New hope for hard-to-treat brain cancer: drug combo shows promise in early trial
NCT ID NCT05253118
First seen Apr 30, 2026 · Last updated May 15, 2026 · Updated 4 times
Summary
This study tests a combination of two drugs, tislelizumab and pemetrexed, in 28 adults with a rare type of brain cancer (primary CNS lymphoma) that has returned or not responded to prior therapy. The goal is to see if the combination can shrink tumors and improve survival. Participants receive the drugs intravenously, and the study is currently active but no longer recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Seoul National University Hospital
Seoul, 03080, South Korea
Conditions
Explore the condition pages connected to this study.